Insilico Medicine Gains MSCI Global Small Cap Index Inclusion
Cambridge, Massachusetts, August 17, 2026 Insilico Medicine, a clinical-stage drug discovery company powered by generative artificial intelligence (AI), announced...
Combination Therapy
Advertisement
PhaseV Survey Highlights Clinical Trial Workflow Delays
Boston, Massachusetts, August 17, 2026 PhaseV, an artificial intelligence and machine learning company focused on clinical development, has announced...
Galmed Reports Aramchol Data in Prostate Cancer Models
Ramat Gan, Israel, August 17, 2026 Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on liver, cardiometabolic, and oncology...
Antag Therapeutics Doses First Patient in Phase 2a Trial of AT7687
COPENHAGEN, Denmark, July 28, 2026 Antag Therapeutics announced that the first patient has been dosed in its Phase 2a...
Akeso Cadonilimab Combo Delivers Strong NSCLC Trial Results
Hong Kong, April 6, 2026 Promising Results in Immunotherapy-Resistant NSCLC In a significant advancement for lung cancer immunotherapy, Akeso,...
Advertisements
Novocure PANOVA-4 Trial Shows Positive Cancer Results
Baar, Switzerland – March 2026 Novocure announced positive topline results from its Phase 2 PANOVA-4 clinical trial evaluating Tumor...
Tau Immunotherapy AADvac1 Enters Landmark AD Trial
SAN FRANCISCO, Calif., Feb. 4, 2026 — Axon Neuroscience announced that its active tau immunotherapy AADvac1 has been selected...
Sagimet Advances MASH Combination Therapy With Phase 1 PK Data
SAN MATEO, Calif., Dec. 18, 2025 — Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company focused on metabolic and fibrotic...
Paxalisib Boosts Anti-Tumor Immunity in Advanced Breast Cancer
SYDNEY, Dec. 10, 2025 — Kazia Therapeutics Limited (NASDAQ: KZIA) unveiled compelling clinical and translational data highlighting the ability...
FDA Approves Jazz Pharma’s Zepzelca + Tecentriq Combo for ES-SCLC
DUBLIN, Oct. 2, 2025 – Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that the U.S. Food and Drug Administration...
Advertisement
